Conjugation of Cholesterol to HIV-1 Fusion Inhibitor C34 Increases Peptide-Membrane Interactions Potentiating Its Action

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Hollmann, Axel ^a   Matos, Pedro M ^a   Augusto, Marcelo T ^a   Castanho, Miguel A R B ^a   Santos, Nuno C ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; C34 PEPTIDE; C34 PEPTIDE CHOLESTEROL CONJUGATE; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; SPHINGOMYELIN; TIFUVIRTIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DERIVATIZATION; DRUG BINDING; DRUG CONJUGATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIPID MONOLAYER; LIPID RAFT; LIPID VESICLE; MEMBRANE BINDING; MEMBRANE FUSION;

AMINO ACID SEQUENCE; BIOLOGICAL TRANSPORT; CELL MEMBRANE; CHOLESTEROL; ERYTHROCYTES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPID BILAYERS; LIPIDS; MEMBRANE FUSION; MEMBRANE MICRODOMAINS; MEMBRANE POTENTIALS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875659806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060302     Document Type: Article

References (51)

1. De Clercq E, (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307-320.
2. Lieberman-Blum SS, Fung HB, Bandres JC, (2008) Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 30: 1228-1250.
3. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, et al. (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3: 215-225.
4. Franquelim HG, Matos PM, Veiga AS (2011) HIV vs. HIV: Turning HIV-Derived Peptides into Drugs. In: Castanho MA, Santos NC, editors. Peptide Drug Discovery and Development. Weinheim, Germany: Wiley-VCH Verlag. 209-229.
5. Naider F, Anglister J, (2009) Peptides in the treatment of AIDS. Curr Opin Struct Biol 19: 473-482.
6. He Y, (2013) Synthesized Peptide Inhibitors of HIV-1 gp41-dependent Membrane Fusion. Curr Pharm Des 19: 1800-1809.
7. Chan DC, Fass D, Berger JM, Kim PS, (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
8. Franquelim HG, Loura LM, Santos NC, Castanho M.A.R.B., (2008) Sifuvirtide screens rigid membrane surfaces. establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J Am Chem Soc 130: 6215-6223.
9. Matos PM, Castanho M.A.R.B., Santos NC, (2010) HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. PLoS ONE 5: e9830.
10. Veiga AS, Santos NC, Loura LM, Fedorov A, Castanho M.A.R.B., (2004) HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J Am Chem Soc 126: 14758-14763.
11. Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, et al. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 106: 5801-5806.
12. Harman S, Herrera C, Armanasco N, Nuttall J, Shattock RJ, (2012) Preclinical Evaluation of the HIV-1 Fusion Inhibitor L'644 as a Potential Candidate Microbicide. Antimicrob Agents Chemother 56: 2347-2356.
13. Peisajovich SG, Gallo SA, Blumenthal R, Shai Y, (2003) C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem 278: 21012-21017.
14. Wexler-Cohen Y, Shai Y, (2007) Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J 21: 3677-3684.
15. Zhang HY, Schneider SE, Bray BL, Friedrich PE, Tvermoes NA, et al. (2008) Process development of TRI-999, a fatty-acid-modified HIV fusion inhibitory peptide. Org Process Res Dev 12: 101-110.
16. Stoddart CA, Nault G, Galkina SA, Thibaudeau K, Bakis P, et al. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283: 34045-34052.
17. Xie D, Yao C, Wang L, Min W, Xu J, et al. (2010) An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54: 191-196.
18. Mayer LD, Hope MJ, Cullis PR, (1986) Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 858: 161-168.
19. Szoka F, Olson F, Heath T, Vail W, Mayhew E, et al. (1980) Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta 601: 559-571.
20. Kubista M, Sjoback R, Eriksson S, Albinsson B, (1994) Experimental correction for the inner-filter effect in fluorescence spectra. Analyst 119: 417-419.
21. Ladokhin AS, Jayasinghe S, White SH, (2000) How to measure and analyze tryptophan fluorescence in membranes properly, and why bother? Anal Biochem 285: 235-245.
22. Brugger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, et al. (2006) The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci U S A 103: 2641-2646.
23. Santos NC, Prieto M, Castanho M.A.R.B., (2003) Quantifying molecular partition into model systems of biomembranes: an emphasis on optical spectroscopic methods. Biochim Biophys Acta 1612: 123-135.
24. Chiu SW, Subramaniam S, Jakobsson E, (1999) Simulation study of a gramicidin/lipid bilayer system in excess water and lipid. II. Rates and mechanisms of water transport. Biophys J 76: 1939-1950.
25. Greenwood AI, Tristram-Nagle S, Nagle JF, (2006) Partial molecular volumes of lipids and cholesterol. Chem Phys Lipids 143: 1-10.
26. Yamazaki M, Miyazu M, Asano T, Yuba A, Kume N, (1994) Direct evidence of induction of interdigitated gel structure in large unilamellar vesicles of dipalmitoylphosphatidylcholine by ethanol: studies by excimer method and high-resolution electron cryomicroscopy. Biophys J 66: 729-733.
27. Santos NC, Prieto M, Castanho M.A.R.B., (1998) Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study. Biochemistry 37: 8674-8682.
28. Nagle JF, Wiener MC, (1988) Structure of fully hydrated bilayer dispersions. Biochim Biophys Acta 942: 1-10.
29. Matos PM, Freitas T, Castanho M.A.R.B., Santos NC, (2010) The role of blood cell membrane lipids on the mode of action of HIV-1 fusion inhibitor sifuvirtide. Biochem Biophys Res Commun 403: 270-274.
30. Gross E, Bedlack RS Jr, Loew LM, (1994) Dual-wavelength ratiometric fluorescence measurement of the membrane dipole potential. Biophys J 67: 208-216.
31. Clarke RJ, Kane DJ, (1997) Optical detection of membrane dipole potential: avoidance of fluidity and dye-induced effects. Biochim Biophys Acta 1323: 223-239.
32. Cladera J, O'Shea P, (1998) Intramembrane molecular dipoles affect the membrane insertion and folding of a model amphiphilic peptide. Biophys J 74: 2434-2442.
33. de Almeida RF, Fedorov A, Prieto M, (2003) Sphingomyelin/phosphatidylcholine/cholesterol phase diagram: boundaries and composition of lipid rafts. Biophys J 85: 2406-2416.
34. Marsh D, (1996) Lateral pressure in membranes. Biochim Biophys Acta 1286: 183-223.
35. Veiga S, Henriques S, Santos NC, Castanho M.A.R.B., (2004) Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem J 377: 107-110.
36. Fernandes MX, Garcia de la Torre J, Castanho M.A.R.B., (2002) Joint determination by Brownian dynamics and fluorescence quenching of the in-depth location profile of biomolecules in membranes. Anal Biochem 307: 1-12.
37. Matos PM, Franquelim HG, Castanho MA, Santos NC, (2010) Quantitative assessment of peptide-lipid interactions. Ubiquitous fluorescence methodologies. Biochim Biophys Acta 1798: 1999-2012.
38. Castanho M.A.R.B., Fernandes MX, (2006) Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the "membrane catalysis" model. Eur Biophys J 35: 92-103.
39. Liu S, Jing W, Cheung B, Lu H, Sun J, et al. (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 282: 9612-9620.
40. Popik W, Alce TM, Au WC, (2002) Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 76: 4709-4722.
41. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE, (2001) Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 17: 1009-1019.
42. Manes S, del Real G, Lacalle RA, Lucas P, Gomez-Mouton C, et al. (2000) Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO reports 1: 190-196.
43. Campbell S, Gaus K, Bittman R, Jessup W, Crowe S, et al. (2004) The raft-promoting property of virion-associated cholesterol, but not the presence of virion-associated Brij 98 rafts, is a determinant of human immunodeficiency virus type 1 infectivity. J Virol 78: 10556-10565.
44. Campbell SM, Crowe SM, Mak J, (2001) Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol 22: 217-227.
45. Beck Z, Brown BK, Wieczorek L, Peachman KK, Matyas GR, et al. (2009) Human erythrocytes selectively bind and enrich infectious HIV-1 virions. PLoS ONE 4: e8297.
46. He W, Neil S, Kulkarni H, Wright E, Agan BK, et al. (2008) Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 4: 52-62.
47. Hess C, Klimkait T, Schlapbach L, Del Zenero V, Sadallah S, et al. (2002) Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 359: 2230-2234.
48. Haldar S, Kanaparthi RK, Samanta A, Chattopadhyay A, (2012) Differential effect of cholesterol and its biosynthetic precursors on membrane dipole potential. Biophys J 102: 1561-1569.
49. Gerber D, Sal-Man N, Shai Y, (2004) Structural adaptation of the glycophorin A transmembrane homodimer to D-amino acid modifications. J Mol Biol 339: 243-250.
50. Vanpouille C, Arakelyan A, Margolis L, (2012) Microbicides: still a long road to success. Trends Microbiol 20: 369-375.
51. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.